BiotechTube

Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent

Conditions

Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers

Trial Timeline

May 2, 2023 → Jul 28, 2023

NCT ID
NCT07116512

About Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B

Finerenone (BAY94-8862): intervention A + Finerenone (BAY94-8862): intervention B is a phase 1 stage product being developed by Bayer for Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent. The current trial status is completed. This product is registered under clinical trial identifier NCT07116512. Target conditions include Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent were approved

Approved (20) Terminated (2) Active (0)
✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
✅ConivaptanAstellas PharmaApproved
✅RegadenosonAstellas PharmaApproved
✅Regadenoson + GadoliniumAstellas PharmaApproved
✅regadenosonAstellas PharmaApproved
✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07116512Phase 1Completed

Competing Products

20 competing products in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
IV Loop DiureticsNuwellisPre-clinical
23
Stepped pharmacologic careNuwellisPhase 3
30
IV Loop Diuretics (LD)NuwellisPre-clinical
8
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35